PROTALIX BIOTHERAPEUTICS INC (PLX)       1.62  -0.01 (-0.61%)

Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment

Protalix BioTherapeutics, Inc. (NYSE AMERICAN: PLX), an Israeli biopharmaceutical company, and Chiesi Global Rare Diseases, a business unit of the Chiesi Group, have resubmitted a Biologics License Application (BLA) for pegunigalsidase alfa (PRX–102), a drug candidate for the treatment of adult patients with Fabry disease.

Under The Hood Of Options Chain Implications — Understanding How Options Data Can Help Inform Investment Decisions

As many investors are aware, options market data can provide some critical insight into future price movements of underlying common stock. It’s often possible to tell how the broader market perceives a company by looking at how options traders are trading it.

Thursday 4/14 Insider Buying Report: PLX, HCP

Best Penny Stocks To Buy? 5 Short Squeeze Stocks To Watch Right Now

5 penny stocks with high short interest to add to your watch list in December.

January 2022 Options Now Available For Protalix BioTherapeutics (PLX)

Interesting PLX Call Options For December 17th

January 2024 Options Now Available For Protalix BioTherapeutics (PLX)

Protalix BioTherapeutics Announces Closing of Private Note Exchange

Protalix BioTherapeutics Reports Second Quarter 2021 Financial Results and Financial and Business Update

Protalix BioTherapeutics Announces Private Note Exchange

Protalix BioTherapeutics to Release Second Quarter 2021 Financial Results and Provide a Financial and Business Update on August 16, 2021

Company to host conference call and webcast at 8:30 a.m. EDT